<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Real-world evidence &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/real-world-evidence/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 25 Oct 2025 12:17:16 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Real-world evidence &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Persistence of Antiretroviral Therapy in HIV Adults</title>
		<link>https://bioengineer.org/persistence-of-antiretroviral-therapy-in-hiv-adults/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 25 Oct 2025 12:17:11 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Antiretroviral therapy adherence]]></category>
		<category><![CDATA[HIV treatment persistence]]></category>
		<category><![CDATA[Mental health comorbidity]]></category>
		<category><![CDATA[Real-world evidence]]></category>
		<category><![CDATA[substance use disorders]]></category>
		<guid isPermaLink="false">https://bioengineer.org/persistence-of-antiretroviral-therapy-in-hiv-adults/</guid>

					<description><![CDATA[In recent years, the intersection of mental health disorders and substance use disorders (SUD) in individuals living with HIV has garnered significant attention from healthcare professionals and researchers alike. A groundbreaking study led by Kong, A.M. and colleagues investigates how real-world persistence is affected in adults diagnosed with HIV, particularly those who also grapple with [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">286801</post-id>	</item>
		<item>
		<title>Managing Metastatic HER2+ Breast Cancer in Greece</title>
		<link>https://bioengineer.org/managing-metastatic-her2-breast-cancer-in-greece/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 01 Oct 2025 21:31:08 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Greece oncology study]]></category>
		<category><![CDATA[metastatic HER2-positive breast cancer]]></category>
		<category><![CDATA[Real-world evidence]]></category>
		<category><![CDATA[second-line therapy outcomes]]></category>
		<category><![CDATA[togetHER study]]></category>
		<guid isPermaLink="false">https://bioengineer.org/managing-metastatic-her2-breast-cancer-in-greece/</guid>

					<description><![CDATA[In the ongoing battle against metastatic HER2-positive breast cancer, a new in-depth study from Greece sheds crucial light on the real-world management and therapeutic outcomes beyond the initial treatment phase. This investigation, titled the togetHER study, analyzes data from patients receiving second-line and subsequent therapies, offering a timely look at clinical realities before new guidelines [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">274736</post-id>	</item>
		<item>
		<title>Prophylaxis Outcomes for Haemophilia B: Extended Half-Life Factors</title>
		<link>https://bioengineer.org/prophylaxis-outcomes-for-haemophilia-b-extended-half-life-factors/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 18 Sep 2025 15:00:51 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Extended half-life factor IX]]></category>
		<category><![CDATA[Hemophilia B prophylaxis]]></category>
		<category><![CDATA[Prophylactic therapy outcomes]]></category>
		<category><![CDATA[Real-world evidence]]></category>
		<category><![CDATA[Treatment adherence]]></category>
		<guid isPermaLink="false">https://bioengineer.org/prophylaxis-outcomes-for-haemophilia-b-extended-half-life-factors/</guid>

					<description><![CDATA[In the evolving landscape of hemophilia treatment, a recent study sheds light on the comparative effectiveness of prophylactic therapies for patients suffering from Hemophilia B. The focus of this research is on extended half-life factor IX therapies, specifically the innovations represented by rIX-FP as compared to rFIXFc and N9-GP. These treatments have been designed to [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">270378</post-id>	</item>
	</channel>
</rss>
